Table 1.
Cohort demographics stratified by positive PPD (≥10 mm).
| TST− (n = 352) |
TST+ (n = 38) |
p-Value | |
|---|---|---|---|
| Age, Mean (SD) | 55.1 (16.6) | 56.4 (13.1) | 0.583 |
| Sex, Female (%) | 163 (46.3%) | 15 (40.5%) | 0.62 |
| Continent | |||
| Africa | 6 (1.7%) | 4 (10.8%) | <0.001 |
| Asia | 75 (21.3%) | 20 (54.1%) | |
| Europe | 28 (8.0%) | 4 (10.8%) | |
| North and South America, Caribbean | 227 (64.5%) | 8 (21.6%) | |
| Missing | 16 (4.5%) | 1 (2.7%) | |
| Diagnosis | |||
| ALL | 76 (21.6%) | 5 (13.5%) | 0.294 |
| AML | 276 (78.4%) | 32 (86.5%) | |
| Induction Chemotherapy | |||
| ATRA-containing regimen | 17 (4.8%) | 0 (0%) | 0.258 |
| Azacitidine | 11 (3.1%) | 1 (2.7%) | |
| Cytarabine | 4 (1.1%) | 1 (2.7%) | |
| Cytarabine + Anthracycline | 1 (0.3%) | 0 (0%) | |
| Cytarabine + Daunorubicin | 180 (51.1%) | 25 (67.6%) | |
| Fludarabine-containing regimen | 39 (11.1%) | 4 (10.8%) | |
| None | 21 (6.0%) | 0 (0%) | |
| Tyrosine-kinase inhibitors | 2 (0.6%) | 1 (2.7%) | |
| Vincristine-containing regimen | 75 (21.3%) | 5 (13.5%) | |
| Vincristine-containing regimen+ Tyrosine-kinase inhibitors | 2 (0.6%) | 0 (0%) | |
| Consolidation Chemotherapy | |||
| ATRA-containing regimen | 16 (4.5%) | 0 (0%) | 0.543 |
| Azacitidine | 6 (1.7%) | 1 (2.7%) | |
| Azacitidine + Allopurinol | 1 (0.3%) | 0 (0%) | |
| Blinatumomab | 1 (0.3%) | 0 (0%) | |
| Cytarabine (high-dose) | 146 (41.5%) | 16 (43.2%) | |
| Fludarabine-containing regimen | 35 (9.9%) | 8 (21.6%) | |
| Hydroxyurea | 1 (0.3%) | 0 (0%) | |
| None | 71 (20.2%) | 6 (16.2%) | |
| Tyrosine-kinase inhibitors | 2 (0.6%) | 0 (0%) | |
| Vincristine-containing regimen | 71 (20.2%) | 6 (16.2%) | |
| Vincristine-containing regimen+ Tyrosine-kinase inhibitors | 2 (0.6%) | 0 (0%) | |
| Re-Induction Chemotherapy | |||
| ATRA-containing regimen | 3 (0.9%) | 0 (0%) | 0.613 |
| Azacitidine | 12 (3.4%) | 4 (10.8%) | |
| Blinatumomab | 8 (2.3%) | 0 (0%) | |
| Cytarabine | 8 (2.3%) | 1 (2.7%) | |
| Cytarabine + ATRA-containing regimen | 1 (0.3%) | 0 (0%) | |
| Cytarabine + Daunorubicin | 5 (1.4%) | 0 (0%) | |
| Fludarabine-containing regimen | 60 (17.0%) | 6 (16.2%) | |
| None | 246 (69.9%) | 25 (67.6%) | |
| Tyrosine-kinase inhibitors | 3 (0.9%) | 0 (0%) | |
| Vincristine-containing regimen | 6 (1.7%) | 1 (2.7%) | |
| Chest Imaging Conducted | |||
| Computerized Tomography | 327 (92.9%) | 37 (97.4%) | 0.496 |
| X-ray | 17 (4.8%) | 0 (0%) | |
| None | 8 (2.3%) | 0 (0%) | |
| Chest Imaging Findings | |||
| Apical Fibrosis | 10 (2.8%) | 3 (8.1%) | 0.0015 |
| Apical Fibrosis, Calcified Granuloma | 1 (0.3%) | 1 (2.7%) | |
| Apical Fibrosis, Consolidation | 6 (1.7%) | 1 (2.7%) | |
| Apical Fibrosis, Lung Nodules | 1 (0.3%) | 1 (2.7%) | |
| Calcified Granuloma | 9 (2.6%) | 5 (13.5%) | |
| Calcified Granuloma, Consolidation | 3 (0.9%) | 0 (0%) | |
| Calcified Granuloma, Pleural Scarring | 1 (0.3%) | 0 (0%) | |
| Calcified Lymph Node, Consolidation | 1 (0.3%) | 0 (0%) | |
| Calcified Lymph Node, Ground-Glass Opacity | 1 (0.3%) | 0 (0%) | |
| Consolidation | 60 (17.0%) | 1 (2.7%) | |
| Consolidation, Lung Nodules | 2 (0.6%) | 0 (0%) | |
| Ground-Glass Opacity | 34 (9.7%) | 7 (18.9%) | |
| Ground-Glass Opacity, Lung Nodules | 1 (0.3%) | 0 (0%) | |
| Hydropneumothorax | 1 (0.3%) | 0 (0%) | |
| Lung Nodules | 26 (7.4%) | 1 (2.7%) | |
| None | 187 (53.1%) | 15 (40.5%) | |
| Opacities | 8 (2.3%) | 2 (5.4%) | |
| Apical Fibrosis | 10 (2.8%) | 3 (8.1%) | 0.0015 |
| Treatment for Latent Tuberculosis Infection | |||
| No Treatment | 346 (98.3%) | 6 (16.2%) | <0.001 |
| Treatment | 6 (1.7%) | 31 (81.6%) | |
| Relapses of Underlying Disease | |||
| None | 243 (69.0%) | 26 (70.3%) | 1 |
| 1 Relapse | 106 (30.1%) | 11 (29.7%) | |
| 2 Relapses | 2 (0.6%) | 0 (0%) | |
| 3 Relapses | 1 (0.3%) | 0 (0%) | |
| Development of Active TB | 0 (0%) | 0 (0%) | <0.001 |
| Treatment for Latent Tuberculosis Infection | |||
| Isoniazid + Vitamin B6 | 6 (100%) | 27 (87.1%) | 1 |
| Other * | 0 (0%) | 4 (12.9%) |
* Other included: isoniazid + vitamin B6 + rifampin (n = 2), rifampin (n = 1) and isoniazid + vitamin B6, then moxifloxacin (n = 1).